A carregar...
Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan
Both overall survival (OS) and progression‐free survival (PFS) are primary endpoints of phase III studies of new anticancer drugs. Medical care expenditures, especially oncology drug prices, are rapidly increasing; however, the impact of oncology drug prices on OS and PFS is unclear. We analyzed the...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6272097/ https://ncbi.nlm.nih.gov/pubmed/30315613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13831 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|